Programs

Grace Science’s unique knowledge and insight about NGLY1 has created opportunities in both rare and common diseases. Synergy across these programs leads to faster and more cost effective drug development and allows us to stay focused and nimble.

PROGRAM
MODALITY
INDICATION
DISCOVERY
PRECLINICAL
PHASE 1/2
PIVOTAL
Neurodegeneration
GS -100
Gene Therapy
NGLY1 Deficiency
GS -310
Small Molecule
Undisclosed
Oncology
GS -220
Small Molecule
Undisclosed
GS -221
Small Molecule
Undisclosed
GS - 100 PROGRAM
MODALITY
INDICATION
Gene therapy
NGLY1 Deficiency
DISCOVERY
PRECLINICAL
PHASE 1/2
PIVOTAL
GS - 310 PROGRAM
MODALITY
INDICATION
Small Molecule
Undisclosed
DISCOVERY
PRECLINICAL
PHASE 1/2
PIVOTAL
GS - 220 PROGRAM
MODALITY
INDICATION
Small Molecule
Undisclosed
DISCOVERY
PRECLINICAL
PHASE 1/2
PIVOTAL
GS - 221 PROGRAM
MODALITY
INDICATION
Small Molecule
Undisclosed
DISCOVERY
PRECLINICAL
PHASE 1/2
PIVOTAL
PROGRAM

NGLY1 Deficiency Gene Therapy

GS-100 is a gene therapy being developed to treat NGLY1 Deficiency, a rare autosomal recessive disease that devastates the central nervous system. GS-100 is an AAV9 single-stranded viral vector that encodes the full length human NGLY1 protein.

Expanded access policy
PROGRAM

Oncology Small Molecule

GS-220 and GS-221 are small molecule inhibitor programs being developed to treat undisclosed cancers. Their target of inhibition is NGLY1, which in turn shuts down NFE2L1, a critical transcription factor that is difficult to inhibit directly.

PROGRAM

Neurodegeneration Small Molecule

GS-310 is a small molecule program for neurodegenerative diseases. Our research has shown that NGLY1 touches many of the same pathways impacted in common neurodegenerative diseases such as Parkinson’s.

We’d Like to Hear From You

contact us